Physician profile
Olawale Morafa
NPI 1013901222
$1,423.01
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $164 · 2021: $361 · 2022: $427.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $489.19 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $240.84 | 2019-2021 | |
| Abbott Laboratories | $238.67 | 2022 | |
| Glaxosmithkline, LLC. | $136.52 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $99.48 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $59.90 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.09 | 2019-2022 | |
| Pfizer INC. | $30.62 | 2019 | |
| Gilead Sciences, INC. | $26.86 | 2021 | |
| Lilly USA, LLC | $24.09 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.75 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olawale Morafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.